SCHEMBL3368965

SCHEMBL3368965

CCCCO/C(=C/c1ccc(OCc2ccccc2)cc1C)C(=O)OC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 1/20 0.47
PLA2G2D Q9UNK4 1/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
HSP90AA1 P07900 1/20 0.44
PSEN1 P49768 3/20 0.44
PTGES O14684 2/20 0.44
ALOX5 P09917 2/20 0.44
PPARG P37231 2/20 0.44
ALDH1A1 P00352 2/20 0.44
L3MBTL1 Q9Y468 3/20 0.43
CYP3A4 P08684 1/20 0.43
TSHR P16473 1/20 0.43
MAPK1 P28482 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
S1PR1 P21453 1/20 0.42
NMT1 P30419 2/20 0.41
LMNA P02545 2/20 0.41
NMT2 O60551 1/20 0.41
NPC1 O15118 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3368964 1.00 NR1H4 (0.47) NR1H4PLA2G2DMEN1KMT2AHSP90AA1
SCHEMBL3368967 1.00 NR1H4 (0.47) NR1H4PLA2G2DMEN1KMT2AHSP90AA1
SCHEMBL3371089 0.86 LTA4H (0.42) PSEN1ALOX5PPARGALDH1A1L3MBTL1
SCHEMBL3372112 0.85 NR1H4 (0.58) NR1H4MEN1KMT2AHSP90AA1PPARG
SCHEMBL5017432 0.85 NR1H4 (0.58) NR1H4MEN1KMT2AHSP90AA1PPARG
SCHEMBL5017434 0.85 NR1H4 (0.58) NR1H4MEN1KMT2AHSP90AA1PPARG
SCHEMBL5607721 0.84 NR1H4 (0.60) NR1H4MEN1KMT2AALDH1A1L3MBTL1
SCHEMBL5607725 0.84 NR1H4 (0.60) NR1H4MEN1KMT2AALDH1A1L3MBTL1
SCHEMBL3370080 0.83 PSEN1 (0.51) NR1H4PLA2G2DMEN1KMT2AHSP90AA1
SCHEMBL3370073 0.83 PSEN1 (0.51) NR1H4PLA2G2DMEN1KMT2AHSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1537091-B1 NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMMA AGONISTS HOFFMANN LA ROCHE (CH) 2010-10-06 EP disclosed
EP-1537091-A1 NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMMA AGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2005-06-08 EP disclosed
US-6809110-B2 NONINSULIN DEPENDENT DIABETES; SUCH AS 2-ETHOXY-3-(4-(2-(5-METHYL-2-PHENYL-THIAZOL-4-YL)-ETHOXY)-BENZO(B)THIOPHEN-7-YL)-PROPIONIC ACID HOFFMANN-LA ROCHE INC. 2004-10-26 US disclosed
US-20040110807-A1 Thiazole derivatives HOFFMANN-LA ROCHE INC. 2004-06-10 US disclosed
WO-2004020420-A1 NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMA AGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2004-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110807-A1 Thiazole derivatives SLC5A1, GPR119, INSR NR1H4 512/4885PLA2G2D 3973/4885MEN1 623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.